About: Antimalarial and cytotoxic drugs on COVID-19 and the cardiovascular burden: Literature review and lessons to be learned

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Antimalarial and cytotoxic drugs on COVID-19 and the cardiovascular burden: Literature review and lessons to be learned Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Antimalarial and cytotoxic drugs on COVID-19 and the cardiovascular burden: Literature review and lessons to be learned
Creator	Acharya, Yogesh Sultan, Sherif
Source	Medline; PMC
abstract	BACKGROUND: The world is witnessing an unprecedented crisis with Coronavirus disease 2019 (COVID-19). It is important to accurately analyze the available evidence to provide correct clinical guidance for optimal patient care. We aim to discuss current clinical evidence regarding chloroquine, hydroxychloroquine, azithromycin, remdesivir, and the cardiovascular burden of COVID-19. METHODS: A literature review was performed using PubMed and Google Scholar. Additional clinical trials were identified through the “TrialsTracker” project. RESULTS: We found conflicting evidence of chloroquine, hydroxychloroquine plus azithromycin, and remdesivir in COVID-19 despite promising early reports of in vitro antiviral activity against severe acute respiratory syndrome coronavirus 2. Some of the current studies have demonstrated adverse drug reactions to chloroquine and hydroxychloroquine + azithromycin. Widespread systemic inflammation and procoagulant/hypercoagulable state, including thrombotic microangiopathy, endothelial dysfunction, bleeding disorder, and thrombosis are increasingly being witnessed in COVID-19. Evidence of cardiac injury and stroke is mostly reported in hospitalized patients; however, large specialized studies that focus on cardiac or neuropathology are lacking. DISCUSSION: There is no convincing clinical evidence of chloroquine, hydroxychloroquine with or without azithromycin, and remdesivir use in COVID-19. As evidence of systemic inflammation is rapidly unfolding, there is a dire need to maximize our resources to find the best possible solutions to the current crisis while conclusive evidence from clinical trials emerges.
has issue date	2020-07-21(xsd:dateTime)
bibo:doi	10.1177/1708538120941635
bibo:pmid	32691699
has license	cc-by
sha1sum (hex)	d25f06a6dfae5e208b4ba0dd25fe4ac8cd55159c
schema:url	https://doi.org/10.1177/1708538120941635
resource representing a document's title	Antimalarial and cytotoxic drugs on COVID-19 and the cardiovascular burden: Literature review and lessons to be learned
has PubMed Central identifier	PMC7375357
has PubMed identifier	32691699
schema:publication	Vascular
resource representing a document's body	covid:d25f06a6dfae5e208b4ba0dd25fe4ac8cd55159c#body_text
is schema:about of	named entity 'chloroquine' named entity 'promising' named entity 'COVID-19' named entity 'demonstrated' named entity 'bleeding disorder' named entity 'COVID-19' named entity 'aim' named entity 'hospitalized' named entity 'unfolding' named entity 'clinical trials' named entity 'drug reactions' named entity 'COVID-19' named entity 'CORONAVIRUS DISEASE 2019' named entity 'INCLUDING' named entity 'POSSIBLE' named entity 'BACKGROUND' named entity 'CONFLICTING' named entity 'REPORTED' named entity 'thrombosis' named entity 'clinical evidence' named entity 'hydroxychloroquine' named entity 'dire' named entity 'Results' named entity 'accurately' named entity 'literature review' named entity 'azithromycin' named entity 'neuropathology' named entity 'systemic inflammation' named entity 'large' named entity 'studies' named entity 'injury' named entity 'systemic inflammation' named entity 'remdesivir' named entity 'specialized' named entity 'Google Scholar' named entity 'patient' named entity 'cardiovascular' named entity 'burden' named entity 'clinical evidence' named entity 'hydroxychloroquine' named entity 'Google Scholar' named entity 'endothelial dysfunction' named entity 'PubMed' named entity 'clinical trials' named entity 'thrombosis' named entity 'COVID' named entity 'thrombotic microangiopathy' named entity 'adverse drug reactions' named entity 'remdesivir' named entity 'clinical evidence' named entity 'cytotoxic drugs' named entity 'Antimalarial' named entity 'COVID-19' named entity 'angiotensin-converting enzyme 2' named entity 'COVID' named entity 'Lancet' named entity 'Dutch' named entity 'clinical trials' named entity 'MERS-CoV' named entity 'disseminated intravascular coagulation' named entity 'HCQ' named entity 'bioinformatics' named entity 'remdesivir' named entity 'DIC' named entity 'hypotension' named entity 'HCQ' named entity 'clinical signs' named entity 'clinical trials' named entity 'risk of death' named entity 'clinical evidence' named entity 'HCQ' named entity 'COVID-19' named entity '19 March' named entity 'ICU' named entity 'Remdesivir' named entity 'SARS' named entity 'hydroxychloroquine' named entity 'troponin' named entity 'Wuhan' named entity 'International Society'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software